2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 818

Cell-Bound Complement Activation Products (CB-CAP) Profiles in Patients with Pre-Systemic Lupus Erythematosus
Abstract Number: 819

Upregulation of Complement C3 and Alpha-2-Macroglobulin in Cerebrospinal Fluid of Neuropsychiatric Systemic Lupus Erythematosus
Abstract Number: 820

Peripheral Blood and Disease Features Associated with Complement Components C3 and C4 in SLE
Abstract Number: 821

Elevated Serum Levels of Soluble CD146 in Patients with Systemic Sclerosis
Abstract Number: 822

Beneficial Effect of Botulinum Toxin-a on Raynaud’s Phenomenon in Japanese Patients with Systemic Sclerosis: A Prospective, Open-Label Trial
Abstract Number: 823

Anti-IFI16 Antibodies in Scleroderma Are Associated with Digital Gangrene
Abstract Number: 824

Familial Risk of Systemic Sclerosis and Co-Aggregation of Autoimmune Diseases in Affected Families: A Nationwide Population Study
Abstract Number: 825

Subclinical Atherosclerosis and Estimation of Cardiovascular Risk in Systemic Sclerosis
Abstract Number: 826

Systemic Sclerosis Inpatient Mortality Has Not Improved from 1995-2011. Results from a National Irish Audit of Scleroderma Co-Morbidities.
Abstract Number: 827

Reliability of the Quantitative Assessment of Peripheral Blood Perfusion By Laser Speckle Contrast Analysis in a Systemic Sclerosis Cohort
Abstract Number: 828

Development of a Disease Damage Index in Systemic Sclerosis Using Consensus and Data Driven Methods
Abstract Number: 829

Fecal Incontinence and Association with Bowel Dysfunction in Systemic Sclerosis: A Canadian Multicenter Study
Abstract Number: 830

Calcinosis Is Associated with Digital Ulcers and Osteoporosis in Patients with Systemic Sclerosis
Abstract Number: 831

Mycophenolate Decreases the Frequency of Endoscopic Therapy for Gastric Antral Vascular Ectasia in Patients with Systemic Sclerosis
Abstract Number: 832

The Validity and Reliability of Online Obituaries As a Source of Mortality Data

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].